Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Ebert

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Gut|June 16, 1999
Induction of TFF1 gene expression in pancreas overexpressing transforming growth factor alphaM P Ebert, J Hoffmann, C Haeckel, et al.
British Journal of Cancer|December 21, 2006
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomasE A Griffiths, S A Pritchard, H R Valentine, et al.
Alimentary Pharmacology & Therapeutics|September 13, 2001
Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasiaJ Yu, W K Leung, E K Ng, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2011
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancerM Moehler, A Mueller, J T Hartmann, et al.
Oncogenesis|January 31, 2017
Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in miceT Feng, J Dzieran, X Yuan, et al.
Zeitschrift Fur Gastroenterologie|March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]M P Ebert, C Auernhammer, K Caca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2013
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)H Fensterer, C Schade-Brittinger, H-H Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb studyB Schultheis, D Reuter, M P Ebert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeM Moehler, A Maderer, C Schimanski, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0M P Ebert, W Fischbach, S Hollerbach, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Gut|June 16, 1999
Induction of TFF1 gene expression in pancreas overexpressing transforming growth factor alphaM P Ebert, J Hoffmann, C Haeckel, et al.
British Journal of Cancer|December 21, 2006
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomasE A Griffiths, S A Pritchard, H R Valentine, et al.
Alimentary Pharmacology & Therapeutics|September 13, 2001
Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasiaJ Yu, W K Leung, E K Ng, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2011
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancerM Moehler, A Mueller, J T Hartmann, et al.
Oncogenesis|January 31, 2017
Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in miceT Feng, J Dzieran, X Yuan, et al.
Zeitschrift Fur Gastroenterologie|March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]M P Ebert, C Auernhammer, K Caca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2013
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)H Fensterer, C Schade-Brittinger, H-H Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb studyB Schultheis, D Reuter, M P Ebert, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeM Moehler, A Maderer, C Schimanski, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0M P Ebert, W Fischbach, S Hollerbach, et al.
Pageof 4